Mechanism of action for pulmonary arterial hypertension medications.

Slides:

Advertisements

Similar presentations

1 Chapter 22 Cyclic Nucleotides in the Nervous System Copyright © 2012, American Society for Neurochemistry. Published by Elsevier Inc. All rights reserved.

Advertisements

Subtypes of Alpha Adrenergic Receptors

Chapter 11: Cell Communication

Part V Second Messengers. The first messengers being the extracellular signal molecules and the third messengers being the large protein kinases and phosphatases.

Section 2, Lecture 2 Cholinergic Receptor Agonists Muscarinic Receptors -smooth muscle -cardiac tissueparasymp. neuroeffector junctions -glands.

Phosphodiesterase(PDE) 5 inhibitor 1. Slidenafil (Viagra) 2. Tadalafil (Cialis) Lee, Sang-Hwi Ref. BMCL 1996, 6, 1819 BMCL 2003, 13, 1425.

Seven-Transmembrane Receptor Signaling Heterotrimeric G-proteins & Second Messenger Pathways.

Second messenger systems: cAMP/cGMP Cyclic nucleotide production & regulation AGC family kinases Biological function.

The Endocrine System: Hormones and Gene Expression Samuel Yang Henok Daniel 4/3/13.

REPRODUCTIVE BEHAVIOR Chapter 11. Mammary Ducts.

Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Efficacy and Safety of Tadalafil in Men With Erectile.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cirrhotic Cardiomyopathy J Am Coll Cardiol. 2010;56(7):

Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Role for peroxynitrite in the inhibition of prostacyclin.

Components of Nucleic Acids

Figure Legend: From: Immune Modulation by Volatile Anesthetics

From: Nitric Oxide: A Physiologic Messenger

Warm-Up Why do you communicate? How do you communicate?

Warm-Up Why do you communicate? How do you communicate?

Cyclic nucleotide signalling in cardiac myocytes and its relation to contraction and arrhythmias. Cyclic nucleotide signalling in cardiac myocytes and.

Cellular Signaling Ch. 11.

Warm-Up Why do you communicate? How do you communicate?

Endothelium-derived mediators: the vasodilators prostacyclin (PGI2) and nitric oxide (NO) and the vasoconstrictor endothelin (ET-1). Endothelium-derived.

Volume 4, Issue 3, Pages (June 2006)

Intracellular Regulation of Ion Channels in Cell Membranes

Signal trasduction via cAMP

Eric Niederhoffer SIU-SOM

HFpEF, a Disease of the Vasculature: A Closer Look at the Other Half

Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model Eric S. Weiss, MD,

Volume 151, Issue 2, Pages (February 2017)

Valerie D. Myers et al. BTS 2018;3:

Figure 1 The role of GPCRs in the regulation of human physiology

Axel Pflueger, MD, Timothy S. Larson, MD, Karl A

The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.

Vascular endothelial dysfunction in cirrhosis

Role of Endothelin in the Pathogenesis of Hypertension

Volume 151, Issue 2, Pages (February 2017)

Divya Gupta et al. JCHF 2013;1:

Androgen effects on bone and muscle

Hao G. Nguyen, MD, PhD, Amit Korach, MD, Chey Collura, MA, Benjamin R

Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid.

Mark S Taylor, A.Marie McMahon, Jason D Gardner, Joseph N Benoit

Joint BES/BBS Seminar Sequential vs initial combination therapy in a rare disease Presenter: Evan Davies 22nd November 2018.

Intracellular cAMP signaling by soluble adenylyl cyclase

The sources of oxidative stress in the vessel wall

Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.

Warm-Up Why do you communicate? How do you communicate?

Beyond Red Hair and Sunburns: Uncovering the Molecular Mechanisms of MC1R Signaling and Repair of UV-Induced DNA Damage Pamela B. Cassidy, Zalfa A. Abdel-Malek,

The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes.

Timeline of approval of therapies for pulmonary arterial hypertension.

Guo-Wei He, MD, DSc, David P. Taggart, FRCS

Margus Annuk, Mihkel Zilmer, Bengt Fellström

Warm-Up Why do you communicate? How do you communicate?

Nitric Oxide Synthase and Adenylyl and Guanylyl Cyclase Activity in Porcine Interposition Vein Grafts Jamie Y Jeremy, PhD, Michael R Dashwood, PhD, Maureen.

Warm-Up Why do you communicate? How do you communicate?

Warm-Up Why do you communicate? How do you communicate?

Warm-Up Why do you communicate? How do you communicate?

Scorpions, snakes, and Fontan failure: The dawn of a new ERA?

Specific signal transduction mechanisms

Evaluation and Medical Management of Erectile Dysfunction

Flow chart showing reinterventions by type in patients with anomalous origin of coronary artery from the pulmonary artery patients, divided into early.

Role of Nitric Oxide Pathway in Placental Dysfunction Following Fetal Bypass Christopher Lam, BS, R. Scott Baker, BS, Jerri McNamara, CCP, Robert Ferguson,

Constantijn Franssen et al. JCHF 2016;4:

Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies Ben M Tsai, MD, Meijing Wang, MD, Mark W Turrentine,

Treatment algorithm. Treatment algorithm. IPAH: idiopathic pulmonary arterial hypertension; APAH: associated pulmonary arterial hypertension; WHO-FC: World.

Figure 4 NOS–NO pathway and therapeutic targets

Polarised enteric motor pathways involved in control of intestinal motor activity. Polarised enteric motor pathways involved in control of intestinal motor.

Biology of endothelin receptors in the collecting duct

Evaluation and Medical Management of Erectile Dysfunction

Jurgen Schnermann, Josephine P. Briggs Kidney International

Platelet activation pathways and sites targeted by current and novel antiplatelet agents. Platelet activation pathways and sites targeted by current and.

Presentation transcript:

Mechanism of action for pulmonary arterial hypertension medications. Mechanism of action for pulmonary arterial hypertension medications. Solid black arrows indicate that the compound stimulates its target, facilitates a reaction or induces a change in vascular tone. Dotted white arrows indicate that the compound inhibits its target. AC, adenylyl cyclase; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; GMP, guanosine monophosphate; GTP, guanosine triphosphate; IP, prostaglandin I2 receptor; NO, nitric oxide; PDE-5, phosphodiesterase-5; PGI2, prostaglandin I2; sGC, soluble guanylyl cyclase. Daniel L Varela et al. Open Heart 2018;5:e000744 ©2018 by British Cardiovascular Society